March 17, 2022 5:32pm

The Biostage (BSTG) Chronicles: shows how the “pimp/pump and promote” works jumping +$0.30 (was +$0.50 the +$0.47) with 1,737 shares traded after Wednesday closed flat with 765 shares traded, Tuesday decline -$0.30 with 380 shares traded and last Monday’s flat with 28 shares traded,

Pre-open indications: 10 Hits, 0 MISS and 1 Pimp/Pump/Promote

What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

The multiple metrics and Bottom Line say it all succinctly … just the facts

Who else is tracking a broad grouping of cell and gene therapy equities – can you afford to not read the facts supported by real numbers?

If I have learned one thing as a former research analyst, venture and public fund investor now a journalist; it is that your life and your bank account are largely tied to your knowledge of price movements and questioning pricing targets.

 

The Dow closed UP +417.66 points (+1.23%); the S&P closed UP +53.81 points (+1.23%) while the Nasdaq closed UP +178.23 points (+1.33%)

 

Henry’omics:

We’re on day three of gains and short-term bullish sentiment in the market and cell and gene therapy sector.

Indexes jumped after stumbling Thursday morning following the Fed’s long-anticipated move to hike short-term interest rates for the first time in three (3) years.

The CBOE volatility index, also known as the “fear gauge”, was down after earlier hitting its lowest level since Feb. 17.

Note: Covered equities dropped – Athersys (ATHX), Caladrius Biosciences (CLBS), - both below $1.00; CEO left - ReNeuron (RENE.L), Stemline Therapeutics (STML) - acquired; added: Agenus (AGEN), AVROBIO (AVRO), Beam Therapeutics (BEAM) and Caribou Biosciences (CRBU). Back to 35 …

Economic Data Docket: Housing starts jumped 6.8% in February to 1.769 million at an annualized rate. Economists expected 1.7 million. The February number was the highest since the summer of 2006. Building permits fell 1.9% to 1.859 million annualized, the first decline in five months.

Weekly jobless claims fell last week as demand for labor remained strong, positioning the economy for another month of solid job gains … Jobless claims fell to 214,000 last week from 229,000. Economists expected 221,000. The latest figure is below the 2019 average of 218,000 as the job market continues to tighten.

 

52-week high:

·         Voyager Therapeutics (VYGR) at $7.64

 

This a.m.’s post, RegMed Investors’ (RMi) pre-open: “don’t get too excited” … https://www.regmedinvestors.com/articles/12345

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened …

  • Thursday opened positive at 32 up/3 downs, 2 flats, stayed positive at the mid-day at 33/2, ending with a positive close of 32/3;

 

Pre-open Indications: 10 Hits < Ionis Pharmaceuticals (IONS +$0.78), Sangamo Therapeutics (SGMO +$0.31), Beam Therapeutics (BEAM +$2.45); SELL into any Strength: Sage Therapeutics (SAGE +$0.44), Voyager Therapeutics (VYGR -$0.26), BioLife Solutions (BLFS +$1.43), CRISPR Therapeutics (CRSP +$1.92), Intellia Therapeutics (NTLA +$3.13), Mesoblast (MESO +$0.17)> 0 Miss > 1 Pimp/Pump/Promote: Biostage (BSTG +$0.47)>    

 

RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628  … (AVRO) added

 

The Biostage (BSTG) Chronicles: shows how the “pimp/pump and promote” works jumping +$0.50, then +$0.30 then +$0.47 with 1,737 shares traded after Wednesday closed flat with 765 shares traded, Tuesday expressed decline of -$0.30 with 380 shares traded, Monday’s flat with 28 shares traded, Friday’s 1,602 shares trading up +$0.39 and last Thursday -$0.63 with 488 shares traded

  • WHO is BUYING these shares of a company with a 3-year-old IND, NO clinical trial initiation, a terminal death lawsuit overhang and a dwindling cash position?
  • A “zombie” company funded by non-U.S. Beijing, China entities
  • By use of the pump/promote process; is BSTG preparing to register the outstanding private placement (PP) shares for a reverse to initiate an offering
  • BSTG is NOT going ANYWHERE without a cash inflow.

 

Key Metrics:

  • Thursday - Sector volume INCREASED with 15 of the 32-upside having higher than the 3-month average volume with LOW volume of 2 of 3-downside having higher than the 3-month average volume;

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Thursday, the IBB was up +2.10% and the XBI was up +3.91%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Thursday was down -1 points or -3.75% at 25.67

 

Jumping with share pricing momentum (15 of 32):

  • Intellia Therapeutics (NTLA +$4.13 after Wednesday’s +$7.65, Tuesday’s -$0.53 and Monday’s -$2.49),
  • Alnylam Pharmaceuticals (ALNY +$4.11 after Wednesday’s +$6.05, Tuesday’s +$1.12 and Monday’s -$3.16),
  • Beam Therapeutics (BEAM +$2.45 after Wednesday’s +$4.60, Tuesday’s +$1.51 and Monday’s -$7.18),
  • Fate Therapeutics (FATE +$2.02 after Wednesday’s +$2.74, Tuesday’s +$1.64 and Monday’s -$3.88),
  • CRISPR Therapeutics (CRSP +$1.92 after Wednesday’s +$5.50, Tuesday’s +$1.98 and Monday’s -$3.36),
  • BioLife Solutions (BLFS +$1.43),
  • uniQure NV (QURE +$1.21 after Wednesday’s +$0.82),
  • Editas Medicine (EDIT +$1.11 after Wednesday’s +$1.25, Tuesday’s +$0.83 and Monday’s -$0.98),
  • Ultragenyx (RARE +$1.10 after Wednesday’s +$4.07, Tuesday’s +$1.49 and Monday’s -$3.21),
  • Global Blood Therapeutics (GBT +$1.06 after Wednesday’s +$1.28),
  • AxoGen (AXGN +$0.92),
  • Ionis Pharmaceuticals (IONS +$0.78 after Wednesday’s +$1.28),
  • Caribou Biosciences (CRBU +$0.64),
  • Regenxbio (RGNX +$0.48 after Wednesday’s +$1.17, Tuesday’s +$1.00 and Monday’s -$2.05),
  • Sage Therapeutics (SAGE +$0.44 after Wednesday’s +$2.09 and Tuesday’s +$0.66),
  • Homology Medicine (FIXX +$0.35),

Hammered in today’s market (3 of 3):

  • Voyager Therapeutics (VYGR -$0.26 after Wednesday’s +$0.79),
  • Pluristem (PSTI -$0.065),
  • Vericel (VCEL -$0.07 after Wednesday’s +$0.86, Tuesday’s +$1.14 and Monday’s -$1.40),

 

March, Q1/2022:

  • Thursday closed positive with 32 incliners and 3 decliners

 

The BOTTOM LINE: The Cell and gene therapy sector held firm without wavering but held major gains though adding slightly to pricings Thursday in its two-day rally.

I would continue SELLING into STRENGTH. this market is full of headline formed landmines.

Thursday was a “follow-through” with the Nasdaq moderately popping.

Reiterating, “The reality continues as investors remain very fearful on adding extra risk in this time of conflict uncertainty.

It’s not the whole picture – the sector needs an action item to offset the divergences to the bottoms.

Awe JUST can NOT depend on algorithmic “rules” …  with the cell and gene therapy sector’s volume remained LOW.

Remember the adage, “It takes two to make a market"; that’s sellers and buyers.

I stick to my view of anticipating the risks – as my careers focus has been “warning analysis”; risk to growth now takes center stage for how long separation of sentiment lasts and how deep the oversold dive.

Q4 and end-of-year earnings are still “gamy” than even I thought.

Earnings’ reporting coming:

·         Brainstorm Cell Therapeutics (BCLI), Monday, 3/28

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

WHY do I keep reporting on Biostage (BSTG): I WAS there to experience what occurred and saw the decay of transparency and more; it defines purpose that takes courage, resolve and patience to stay the course of asking the questions without response!